Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR52 | Q9Y2T5 | 15/20 | 0.50 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.44 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.44 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.44 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.36 |
| ▸ | FEN1 | P39748 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3075444 | 0.84 | GPR52 (0.47) | GPR52PIK3CDPIK3CAPIK3CGPIK3CB | |
| SCHEMBL2074226 | 0.80 | PIK3CD (0.65) | GPR52PIK3CDPIK3CAPIK3CGPIK3CB | |
| SCHEMBL3099579 | 0.79 | PIK3CG (0.69) | PIK3CDPIK3CAPIK3CGPIK3CB | |
| SCHEMBL2958703 | 0.78 | PIK3CD (0.59) | GPR52PIK3CDPIK3CAPIK3CGPIK3CB | |
| SCHEMBL3164908 | 0.73 | IKBKB (0.38) | GPR52PIK3CDPIK3CAPIK3CGPIK3CB | |
| SCHEMBL688062 | 0.72 | CDC7 (0.46) | PIK3CDPIK3CAPIK3CGPIK3CB | |
| SCHEMBL5048901 | 0.72 | GPR52 (0.56) | GPR52 | |
| SCHEMBL3156596 | 0.71 | CCNC (0.46) | GPR52PIK3CDPIK3CAPIK3CGPIK3CB | |
| SCHEMBL10367425 | 0.70 | SIRT3 (0.48) | PIK3CDPIK3CAPIK3CGPIK3CB | |
| SCHEMBL3668739 | 0.70 | GPR52 (0.44) | GPR52 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7799810-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-09-21 | — | — | US | disclosed |
| US-20100120865-A1 | Organic compounds | NOVARTIS AG (CH) | 2010-05-13 | — | — | US | disclosed |
| EP-2035413-A2 | THIAZOLYL UREA DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | Novartis AG (CH) | 2009-03-18 | — | — | EP | disclosed |
| WO-2008000421-A2 | THIAZOLYL UREA DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120865-A1 | Organic compounds | PIK3C3, PIK3R3, PIK3R4 | GPR52 2380/4885PIK3CD 10/4885PIK3CA 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.